Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
34
ALXO Quote, Financials, Valuation and Earnings
Last price:
$1.42
Seasonality move
:
55.36%
Day range:
$1.37 - $1.48
52-week range:
$0.40 - $2.27
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
8.93x
P/B ratio:
1.72x
Volume:
266.3K
Avg. volume:
314.4K
1-year change:
-21.55%
Market cap:
$77M
Revenue:
--
EPS (TTM):
-$2.03
Analysts' Opinion
-
Consensus RatingALX Oncology Holdings, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.00, ALX Oncology Holdings, Inc. has an estimated upside of 111.27% from its current price of $1.42.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $1.42.
Fair Value
-
According to the consensus of 4 analysts, ALX Oncology Holdings, Inc. has 111.27% upside to fair value with a price target of $3.00 per share.
ALXO vs. S&P 500
-
Over the past 5 trading days, ALX Oncology Holdings, Inc. has overperformed the S&P 500 by 3.33% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ALX Oncology Holdings, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ALX Oncology Holdings, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter ALX Oncology Holdings, Inc. reported revenues of --.
Earnings Growth
-
ALX Oncology Holdings, Inc. has grown year-over-year earnings for 7 quarters straight. In the most recent quarter ALX Oncology Holdings, Inc. reported earnings per share of -$0.41.
Enterprise value:
32M
EV / Invested capital:
0.53x
Price / LTM sales:
8.93x
EV / EBIT:
--
EV / Revenue:
-15.06x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.33x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$769K
Return On Assets:
-85.39%
Net Income Margin (TTM):
--
Return On Equity:
-120.56%
Return On Invested Capital:
-101.77%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$1.7M | -$865K | -$769K | -$224K | -$153K | |
| Operating Income | -$154.5M | -$159.9M | -$108.4M | -$32.6M | -$22.5M | |
| EBITDA | -$152.8M | -$159M | -$107.7M | -$32.3M | -$22.4M | |
| Diluted EPS | -$3.57 | -$2.98 | -$2.03 | -$0.58 | -$0.41 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $389M | $290.8M | $199.1M | $155.9M | $66.5M | |
| Total Assets | $399.7M | $317.7M | $220.1M | $185.7M | $82.7M | |
| Current Liabilities | $12.5M | $25.2M | $35.1M | $32.3M | $27.7M | |
| Total Liabilities | $14.6M | $30.7M | $51.4M | $48.9M | $37.9M | |
| Total Equity | $385.2M | $287M | $168.8M | $136.8M | $44.8M | |
| Total Debt | $2.8M | $5.9M | $14.2M | $16.4M | $14.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$111.4M | -$129.5M | -$97.2M | -$25.4M | -$17.1M | |
| Cash From Investing | $72.3M | $36.4M | $104.5M | $25.7M | $21.4M | |
| Cash From Financing | $9.6M | $89.7M | $12K | $251K | -$159K | |
| Free Cash Flow | -$112.9M | -$130.1M | -$97.4M | -$25.5M | -$17.1M | |
ALXO
Sector
Market Cap
$77M
$28.5M
Price % of 52-Week High
62.56%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-0.43%
-1.33%
1-Year Price Total Return
-21.55%
-20.32%
Beta (5-Year)
0.526
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$1.35
200-day SMA
Buy
Level
$0.92
Bollinger Bands (100)
Buy
Level
0.79 - 1.67
Chaikin Money Flow
Sell
Level
-34.9M
20-day SMA
Buy
Level
$1.38
Relative Strength Index (RSI14)
Buy
Level
50.17
ADX Line
Sell
Level
16.02
Williams %R
Neutral
Level
-52.1739
50-day SMA
Sell
Level
$1.57
MACD (12, 26)
Sell
Level
-0.04
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
37.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-6.5688)
Sell
CA Score
(Annual)
Level (-2.4844)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (6)
Sell
Ohlson Score
Level (7.6248)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. Its objective is to provide clinical therapies for the treatment of myelodysplastic syndromes, acute myeloid leukemia, and a range of solid tumor indications. The company was founded by Corey Goodman, Jaume Pons, and K. Christopher Garcia in March 2015 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, ALXO has received 3 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ALXO average analyst price target in the past 3 months is $3.00.
-
Where Will ALX Oncology Holdings, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that ALX Oncology Holdings, Inc. share price will rise to $3.00 per share over the next 12 months.
-
What Do Analysts Say About ALX Oncology Holdings, Inc.?
Analysts are divided on their view about ALX Oncology Holdings, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ALX Oncology Holdings, Inc. is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is ALX Oncology Holdings, Inc.'s Price Target?
The price target for ALX Oncology Holdings, Inc. over the next 1-year time period is forecast to be $3.00 according to 4 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ALXO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ALX Oncology Holdings, Inc. is a Buy. 3 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ALXO?
You can purchase shares of ALX Oncology Holdings, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ALX Oncology Holdings, Inc. shares.
-
What Is The ALX Oncology Holdings, Inc. Share Price Today?
ALX Oncology Holdings, Inc. was last trading at $1.42 per share. This represents the most recent stock quote for ALX Oncology Holdings, Inc.. Yesterday, ALX Oncology Holdings, Inc. closed at $1.42 per share.
-
How To Buy ALX Oncology Holdings, Inc. Stock Online?
In order to purchase ALX Oncology Holdings, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ALXO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ALXO
Sector
P/E ratio
--
23.75x
PEG ratio
--
-0.01x
P/B ratio
1.72x
1.83x
Price / LTM sales
8.93x
1.60x
Growth Metrics
ALXO
Sector
Revenue growth
--
4.85%
Earnings growth
29.07%
11.11%
Revenue (5-year growth)
-100%
6.45%
Earnings forecast
-$0.26
-$0.20
Profitability
ALXO
Sector
Profitability FY 2024
-$872K
$3.6M
Return on invested capital
-101.77%
-30.98%
Return on assets
-85.39%
-27.62%
Return on equity
-120.56%
-36.69%
Earnings Date
Last Earnings Date
Nov
7
Next Earnings Date
Mar
5
Estimated Next Earnings Date
Feb
6
Balance Sheet
ALXO
Sector
Total cash
$60.6M
$27.2M
Short term investments
$110.2M
$25.7M
Total assets
$147.8M
$79.7M
Long term debt
$14.6M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
